-
2020.12.10
Ethical Drugs
- Notice regarding The Launch of Rivastigmine Tapes 4.5 mg / 9 mg / 13.5 mg / 18 mg “Hisamitsu”, Transdermal Patches for The Treatment of Alzheimer’s Dementia
-
2020.12.07
Research and Development
- Notification of the results of Phase Ⅲ clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)
-
2020.10.19
Other
- Notice regarding The Provision of “Air® Salonpas®” to The Member Organizations of The Japanese Olympic Committee (JOC)
-
2020.10.19
Other
- Notice regarding The Provision of “Air® Salonpas®” to The Member Organizations of The Japanese Paralympic Committee (JPC)
-
2020.10.08
lR Information
- FY02/2021 Q2 Results Earnings Release Presentation
-
2020.10.07
Research and Development
- Notification of the commencement of the Phase III clinical study of HP-5070 in Japan (primary palmar hyperhidrosis treatment drug)
-
2020.09.10
Ethical Drugs
- Notification of application for manufacturing and marketing approval of the additional indications of cancer pain relief for pediatric patients of Fentos®Tape (Transdermal, pain management patch,Development code: HFT-290) in Japan
-
2020.08.07
Other
- Conclusion of Cooperation Agreement with Tosu City
-
2020.08.05
Other
- Notice regarding Providing Relief Supplies in Response to The Torrential Rains in July 2020
-
2020.07.29
Management and Personnel
- Notice Regarding Resignation of Board of Director and Post After Resignation
-
2020.07.28
lR Information
- Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
-
2020.07.21
Ethical Drugs
- Notification of approval for manufacturing and marketing approval of OABLOK® PATCH in Thailand (Transdermal, Overactive bladder treatment patch)
-
2020.07.13
Ethical Drugs
- Notice regarding Application for Approval of Partial Change of Approved Matters of “Mohrus® Paps XR 120 mg and 240 mg”, Transdermal Analgesic Anti-Inflammatory Patches
-
2020.07.13
Other
- Notice regarding Support for The Disaster of The Torrential Rains in July 2020
-
2020.07.09
lR Information
- FY02/2021 Q1 Results Earnings Release Presentation
-
2020.07.09
lR Information
- Notice regarding Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
-
2020.07.09
lR Information
- Notice regarding Earnings Forecast and Dividend Forecast
-
2020.06.29
Ethical Drugs
- Notification of approval for manufacturing and marketing approval of the additional indications of cancer pain relief for opioid analgesic naïve patients of Fentos®Tape (Transdermal, pain management patch, Development code: HFT-290) in Japan
-
2020.05.21
Management and Personnel
- Executive Appointments
-
2020.05.18
Other
- Salonpas®Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Fourth Consecutive Year
-
2020.05.15
Other
- Lighting up the Salonpas billboard at Shibuya Scramble Crossing in blue to express gratitude to the Frontline Healthcare Workers.
-
2020.04.10
Management and Personnel
- Executive Appointments
-
2020.04.10
lR Information
- FY02/2020 Q4 Results Earnings Release Presentation
-
2020.04.06
Ethical Drugs
- Notification of marketing of Secuado® in the US (Transdermal, Schizophrenia treatment patch, Development code: HP-3070)
-
2020.03.04
Subsidiaries and Affiliated Companies
- Notice regarding The Establishment of SAGA Hisamitsu Springs Co., Ltd., The Management Company of Women’s Volleyball Hisamitsu Springs
-
2020.02.27
Research and Development
- Notification of application for manufacturing and marketing approval of HP-3150 for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch)
-
2020.01.31
Other
- Notice regarding Conclusion of “Agreement on Support and Cooperation in The Event of a Disaster” with the Japanese Red Cross Society
-
2020.01.23
Other
- Acquisition of ISO 45001 Certification (Occupational Health and Safety Management System)
-
2020.01.10
lR Information
- FY02/2020 Q3 Results Earnings Release Presentation
-
2020.01.10
Subsidiaries and Affiliated Companies
- Announcement of Establishment of New Company in Malaysia
-
2020.01.09
Research and Development
- Notification of the commencement of Phase III clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)
-
2020.01.07
Other
- Notice regarding The Decision to Contribute to Supporting Organizations in FY 2019 through Hisamitsu Pharmaceutical Co., Inc. Hot Heart Club
